Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Oculus Innovative Sciences, Inc. (OCLS - Snapshot Report) was greeted with good news, when the U.S. Food and Drug Administration (FDA) cleared its new Microcyn Scar Management HydroGel. Oculus shares soared 103.4% following the news and ended at $4.74 on Dec 4. The stock also touched a 52-week high of $7.21 during the course of the trading session on that day.

Oculus received a 510(k) clearance from the U.S. regulatory body for Microcyn Scar Management HydroGel for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds. The product is approved for the indication under a healthcare professional’s supervision. The FDA clearance of Microcyn Scar Management HydroGel was based on positive results from a double-blind, multi-center, randomized clinical study (n=40).

Oculus expects its U.S. partner, Quinnova Pharmaceuticals, to launch Microcyn Scar Management HydroGel in the first half of 2014. Oculus is also working with other partners to make the product available around the globe.

The company expects Microcyn Scar Management HydroGel to be available in Mexico in 2014 through its Latin American partner, More Pharma. Oculus also expects the scar product to be available in countries like China, Singapore, Malaysia, India, Kuwait, UAE, Jordan and Iraq after Apr 2014.

We are encouraged by the U.S. approval of scar product. We expect investor focus to stay on the product’s launch across the globe in the coming quarters.

Oculus presently carries a Zacks Rank #4 (Sell). Some better ranked stocks include Actelion Ltd. (ALIOF), Lannett Company, Inc. (LCI - Snapshot Report) and AMAG Pharmaceuticals, Inc. (AMAG - Snapshot Report). While Actelion and Lannett hold a Zacks Rank #1 (Strong Buy), AMAG carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%